Category: H.C
-
H.C. Wainwright optimistic on Biophytis stock as Phase 2 trial approved By Investing.com
•
HC Wainwright on Friday affirmed its buy rating and $15.00 price target on Biophytis SA (NASDAQ:BPTS) stock, following the company’s announcement that it has received FDA approval to begin a Phase 2 clinical study. The study, which will focus on BIO101 in patients with obesity, is scheduled to begin in…
-
Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com
•
On Friday, HC Wainwright reaffirmed a Buy rating on biopharmaceutical company argenx SE (NASDAQ: ARGX), with a firm price target of $448.00. The Company’s confidence in argenx is rooted in the Company’s successful introduction of Vyvgart for the treatment of myasthenia gravis (MG), which has been recognized as one of…